The common loss of SMAD4 in PDAC results in the upregulation of TGF-β signalling, which aids in tumour progression via the activation of MAPK/ERK, PI3K/AKT, p38 MAPK and Rho-GTPase pathway signalling [31]. Here, SMAD4 is linked to neoplasm.